other material
confidence high
sentiment neutral
materiality 0.50
Vistagen shareholders approve reverse stock split authorization up to 1-for-30; bylaw amendment fails
Vistagen Therapeutics, Inc.
- Proposal 5 passed: 104.2M for, 25.4M against; board may implement reverse split at 1:2 to 1:30 ratio.
- Proposal 6 failed: 65.6M for short of 103.4M majority needed; board cannot unilaterally set director count.
- Reverse split authorization expires October 14, 2023; board may act anytime before then.